Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect and Safety of Recombinant Human Fibroblast Growth Factor-1 for Patient With Carpal Tunnel Syndrome

NCT06328166 is registered in ClinicalTrials.gov with Tri-Service General Hospital (TSGH) as lead sponsor.

NCT NCT06328166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06328166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect and Safety of Recombinant Human Fibroblast Growth Factor-1 for Patient With Carpal Tunnel Syndrome
Lead sponsor
Tri-Service General Hospital (TSGH)
Phase
Not applicable
Overall status
Completed
Start date
March 22, 2024
Completion date
May 30, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carpal tunnel syndrome